Unternehmen wird geladen
Just reported
Q2 FY2027 results
From Mckesson's results release of 4. November 2026; its quarterly report has since been filed.
Revenue
Actual
110,96B $
+7,6 % y/y
+5,3 % q/qGuided
—
No guide given
EPS, GAAP
Actual
10,44 $
+17 % y/y
+103 % q/qGuided
—
No guide given
EPS, adjusted: 11,68 $
Operating income, GAAP
Actual
1,6B $
+14 % y/y
+22 % q/qGuided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted45,60 $ – 46,40 $Raised +3,1 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Mckesson is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- Prescription-drug distribution in the United States and Canada84 %
- Oncology and multispecialty distribution and provider services12 %
- Medical, surgical, and laboratory distribution3 %
- Prescription technology and biopharmaceutical services1 %
Die Umsatzanteile sind Schätzungen für FY2026 ended 2026-03-31 und keine Zahlen aus einem eingereichten Bericht.
Konkurriert mit
Was es verkauft6
Prescription-drug distribution
Wholesale supply and delivery of branded, generic, specialty, biosimilar, and over-the-counter medicines to pharmacies and health providers.
Pharmacy business services
Financial, operational, clinical, consulting, and technology services for retail, hospital, and other pharmacies.
Oncology and multispecialty provider services
Specialty-drug distribution, infusion services, direct-to-patient pharmacy services, and support for community oncology and other specialty-care practices.
3 weitere anzeigen
Prescription access and affordability services
Services that help check insurance coverage, obtain prior authorization, compare prescription prices, support dispensing, and enroll patients in assistance programs.
Biopharmaceutical logistics and distribution
Storage, transport, and distribution services for biopharmaceutical manufacturers, including products requiring temperature-controlled handling.
Medical, surgical, and laboratory supplies
Distribution of branded and McKesson's own medical, surgical, and laboratory products to care providers outside acute-care hospitals.
Wer es kauft5
- Retail and hospital pharmacies buy medicines and pharmacy services.
- Hospitals and other institutional health providers buy medicines, including specialty drugs.
- Oncology and multispecialty practices use drug distribution, practice support, infusion, and related services.
2 weitere anzeigen
- Biopharmaceutical manufacturers use logistics, distribution, and patient access services.
- Physician offices, surgery centers, nursing homes, hospice providers, and home health agencies buy medical and surgical supplies.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1Drug distribution depends on manufacturers supplying medicines and on manufacturer pricing, which can change the reported value of sales.
- 2Operations depend on information systems and networks for distribution, customer services, and technology products.
- 3Changes to drug-pricing rules, the federal 340B Drug Pricing Program, or government funding of health care can affect the pharmaceutical supply chain and McKesson's services.
Was schiefgehen könnte
- 1Cybersecurity incidents could compromise McKesson's technology systems or expose sensitive data.
- 2Problems with information systems or networks, or technology products that do not work as intended, could disrupt operations or customer services.
- 3Changes in government health policy, drug pricing, the 340B Drug Pricing Program, or government funding could affect the company's operations and participants in the pharmaceutical supply chain.
Über Mckesson Corporation
McKesson buys medicines from manufacturers and sells and delivers them to pharmacies, hospitals, and other care providers. It also distributes specialty medicines and supports community oncology practices with services, research, and technology. Its prescription services help connect patients, pharmacies, providers, health plans, and drug manufacturers to handle coverage checks, prior authorization, and affordability programs. It also supplies medical, surgical, and laboratory products to care providers outside hospitals.
- Hauptsitz
- Irving, Texas, United States
- Gegründet
- 1833 (year founded, high confidence)
- Beschäftigte
- 43,000 (FY2026, high)
- Notiert an
- New York Stock Exchange
- Geschäftsjahresende
- March 31
Gebaut aus den eigenen Einreichungen von Mckesson Corporation bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
